Equillium (0A4D) Stock Overview
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
0A4D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Equillium, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$2.61 |
| 52 Week Low | US$0.28 |
| Beta | 1.83 |
| 1 Month Change | 11.24% |
| 3 Month Change | 16.41% |
| 1 Year Change | 357.48% |
| 3 Year Change | 209.72% |
| 5 Year Change | -75.49% |
| Change since IPO | -66.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -15.7% | -5.3% | 0.4% |
| 1Y | 357.5% | 15.2% | 15.0% |
Return vs Industry: 0A4D exceeded the UK Biotechs industry which returned 15.2% over the past year.
Return vs Market: 0A4D exceeded the UK Market which returned 15% over the past year.
Price Volatility
| 0A4D volatility | |
|---|---|
| 0A4D Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.0% |
Stable Share Price: 0A4D's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A4D's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 35 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma.
Equillium, Inc. Fundamentals Summary
| 0A4D fundamental statistics | |
|---|---|
| Market cap | US$116.70m |
| Earnings (TTM) | -US$22.40m |
| Revenue (TTM) | n/a |
Is 0A4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4D income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.40m |
| Earnings | -US$22.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0A4D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/28 18:37 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Equillium, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Biren Amin | Jefferies LLC |
| Roger Song | Jefferies LLC |
| Catherine Novack | JonesTrading Institutional Services, LLC |